2018 World Conference on Lung Cancer *

September 23-26, 2018; Toronto, Canada
Review slidesets and expert analysis of key data from the 2018 WCLC annual meeting.

Share

Program Content

Activities

ALTA-1: Brigatinib
ALTA-1L: Phase III Trial of Brigatinib vs Crizotinib in ALK Inhibitor–Naive Patients With ALK-Positive Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 27, 2018

Expires: September 26, 2019

IMpower132: Atezolizumab
Phase III IMpower132: Addition of Atezolizumab to First-line Carboplatin/Cisplatin + Pemetrexed in Stage IV Nonsquamous NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2018

Expires: September 27, 2019

IMpower133: Atezo in ES-SCLC
IMpower133: Addition of Atezolizumab to First-line Carboplatin/Etoposide in Extensive-Stage Small-Cell Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2018

Expires: September 27, 2019

PACIFIC: Durvalumab in Stage III NSCLC
PACIFIC: Improved OS With Durvalumab vs Placebo After CRT in Unresectable Stage III NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2018

Expires: September 27, 2019

Entrectinib in <i>ROS1</i> NSCLC
Entrectinib in ROS1-Positive NSCLC: Pooled Analysis of 3 Early-Phase Studies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2018

Expires: October 01, 2019

Poziotinib in <i>EGFR/HER2</i> Exon 20–Mutated NSCLC
Phase II Study of Poziotinib, an Investigational TKI, in Heavily Pretreated EGFR or HER2 Exon 20–Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2018

Expires: October 01, 2019

NELSON: Low-Dose CT Screening
NELSON: Reduced 10-Yr Lung Cancer Mortality With Low-Dose CT Screening in High-Risk Current and Former Smokers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2018

Expires: October 01, 2019

ALTER1202: Anlotinib in SCLC
Phase II ALTER1202: Randomized Trial of Anlotinib for SCLC in the Third-line Setting and Beyond
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 02, 2018

Expires: October 01, 2019

Provided by

ProCE Banner

Supporters

Supported by educational grants

AbbVie

AstraZeneca

Genentech TEXT Only

Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.